Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK)
HKD 1.39
(-0.71%)
HKD 1.39
(-0.71%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 838.44 Million CNY | 10.24% |
| 2022 | 760.54 Million CNY | 22.95% |
| 2021 | 618.56 Million CNY | 34.76% |
| 2020 | 459.02 Million CNY | 6.02% |
| 2019 | 432.94 Million CNY | 2.64% |
| 2018 | 421.81 Million CNY | 85.79% |
| 2017 | 227.04 Million CNY | 8.83% |
| 2016 | 208.63 Million CNY | 13.36% |
| 2015 | 184.03 Million CNY | 3.77% |
| 2014 | 177.34 Million CNY | 0.43% |
| 2013 | 176.59 Million CNY | 24.54% |
| 2012 | 141.79 Million CNY | 22.97% |
| 2011 | 115.31 Million CNY | 30.95% |
| 2010 | 88.05 Million CNY | 10.33% |
| 2009 | 79.81 Million CNY | -5.19% |
| 2008 | 84.18 Million CNY | 70.72% |
| 2007 | 49.3 Million CNY | 16.95% |
| 2006 | 42.16 Million CNY | 1.21% |
| 2005 | 41.65 Million CNY | 0.54% |
| 2004 | 41.43 Million CNY | 1.85% |
| 2003 | 40.68 Million CNY | 5.56% |
| 2002 | 38.53 Million CNY | -30.7% |
| 2001 | 55.61 Million CNY | 20.66% |
| 2000 | 46.09 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 780.16 Million CNY | -6.95% |
| 2024 Q2 | 780.16 Million CNY | 0.0% |
| 2023 Q2 | 725.63 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2023 Q1 | - CNY | -100.0% |
| 2023 FY | 838.44 Million CNY | 10.24% |
| 2023 Q4 | 838.44 Million CNY | 0.0% |
| 2022 FY | 760.54 Million CNY | 22.95% |
| 2022 Q4 | 760.54 Million CNY | 0.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 Q2 | 632.52 Million CNY | 0.0% |
| 2021 FY | 618.56 Million CNY | 34.76% |
| 2021 Q2 | 499.88 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 Q4 | 618.56 Million CNY | 0.0% |
| 2020 FY | 459.02 Million CNY | 6.02% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q2 | 406.93 Million CNY | 0.0% |
| 2020 Q4 | 459.02 Million CNY | 0.0% |
| 2019 Q4 | 432.94 Million CNY | 0.0% |
| 2019 Q2 | 388.79 Million CNY | 0.0% |
| 2019 FY | 432.94 Million CNY | 2.64% |
| 2018 Q1 | - CNY | -100.0% |
| 2018 Q4 | 421.81 Million CNY | 0.0% |
| 2018 Q2 | 251.84 Million CNY | 0.0% |
| 2018 FY | 421.81 Million CNY | 85.79% |
| 2017 Q2 | 296.31 Million CNY | 0.0% |
| 2017 Q4 | 227.04 Million CNY | 0.0% |
| 2017 FY | 227.04 Million CNY | 8.83% |
| 2017 Q1 | - CNY | -100.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 208.63 Million CNY | 13.36% |
| 2016 Q4 | 208.63 Million CNY | 0.0% |
| 2016 Q2 | 229.94 Million CNY | 0.0% |
| 2015 Q1 | - CNY | -100.0% |
| 2015 Q2 | 185.81 Million CNY | 0.0% |
| 2015 Q4 | 184.03 Million CNY | 0.0% |
| 2015 FY | 184.03 Million CNY | 3.77% |
| 2014 Q4 | 177.34 Million CNY | 0.0% |
| 2014 FY | 177.34 Million CNY | 0.43% |
| 2014 Q2 | 201.92 Million CNY | 0.0% |
| 2014 Q1 | - CNY | -100.0% |
| 2013 Q1 | - CNY | -100.0% |
| 2013 Q4 | 176.59 Million CNY | 0.0% |
| 2013 Q2 | 206.45 Million CNY | 0.0% |
| 2013 FY | 176.59 Million CNY | 24.54% |
| 2012 Q4 | 141.79 Million CNY | 0.0% |
| 2012 Q2 | 129.5 Million CNY | 0.0% |
| 2012 FY | 141.79 Million CNY | 22.97% |
| 2011 Q4 | 115.31 Million CNY | 0.0% |
| 2011 FY | 115.31 Million CNY | 30.95% |
| 2011 Q2 | 113.89 Million CNY | 0.0% |
| 2010 Q4 | 88.05 Million CNY | 0.0% |
| 2010 Q2 | 102.87 Million CNY | 0.0% |
| 2010 FY | 88.05 Million CNY | 10.33% |
| 2009 FY | 79.81 Million CNY | -5.19% |
| 2008 FY | 84.18 Million CNY | 70.72% |
| 2007 FY | 49.3 Million CNY | 16.95% |
| 2006 FY | 42.16 Million CNY | 1.21% |
| 2005 FY | 41.65 Million CNY | 0.54% |
| 2004 FY | 41.43 Million CNY | 1.85% |
| 2003 FY | 40.68 Million CNY | 5.56% |
| 2002 FY | 38.53 Million CNY | -30.7% |
| 2001 FY | 55.61 Million CNY | 20.66% |
| 2000 FY | 46.09 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -489.283% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 88.427% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -392.024% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -18.148% |
| Qianhai Health Holdings Limited | 94 Million HKD | -791.933% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 9.851% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 7.229% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -26.008% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -21.575% |
| SSY Group Limited | 4.49 Billion HKD | 81.343% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -128.613% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 23.113% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.502% |